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Abstract
Background: Septic shock (SS) and cardiogenic shock (CS) are two types of circulatory shock with a different
etiology. Several studies have described the molecular alterations in SS patients, whereas the molecular factors
involved in CS have been poorly investigated. We aimed to assess in the whole blood of CS and SS patients, using
septic patients without shock (SC) as controls, transcriptomic modifications that occur over 1 week after ICU
admission and are common to the two types of shock.
Methods: We performed whole blood RNA sequencing in 21 SS, 11 CS, and 5 SC. In shock patients, blood samples
were collected within 16 h from ICU admission (T1), 48 h after ICU admission (T2), and at day 7 or before discharge
(T3). In controls, blood samples were available at T1 and T2. Gene expression changes over time have been studied
in CS, SS, and SC separately with a paired analysis. Genes with p value < 0.01 (Benjamini-Hochberg multiple test
correction) were defined differentially expressed (DEGs). We used gene set enrichment analysis (GSEA) to identify
the biological processes and transcriptional regulators significantly enriched in both types of shock.
Results: In both CS and SS patients, GO terms of inflammatory response and pattern recognition receptors (PRRs)
were downregulated following ICU admission, whereas gene sets of DNA replication were upregulated. At the gene
level, we observed that alarmins, interleukin receptors, PRRs, inflammasome, and DNA replication genes significantly
changed their expression in CS and SS, but not in SC. Analysis of transcription factor targets showed in both CS and SS
patients, an enrichment of CCAAT-enhancer-binding protein beta (CEBPB) targets in genes downregulated over time
and an enrichment of E2F targets in genes with an increasing expression trend.
Conclusions: This pilot study supports, within the limits of a small sample size, the role of alarmins, PRRs, DNA
replication, and immunoglobulins in the pathophysiology of circulatory shock, either in the presence of infection or
not. We hypothesize that these genes could be potential targets of therapeutic interventions in CS and SS.
Trial registration: ClinicalTrials.gov, NCT02141607. Registered 19 May 2014.
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Background
Circulatory shock is a common life-threatening condi-
tion in critical care that affects approximately one third
of all patients admitted to the intensive care unit (ICU),
with accompanying high mortality [1, 2]. Circulatory
shock is characterized by systemic arterial hypotension
associated with tissue hypoperfusion, acidemia, and in-
creased blood lactate levels that reflect resultant tissue
hypoxia, which in turn may lead to multi-system organ
failure and eventual death [3]. Septic shock (SS) and car-
diogenic shock (CS) are two forms of circulatory shock
with different etiologies but similar end-organ effects.
SS, the most common form of shock in the ICU, is a
cardiovascular complication of sepsis resulting from a
complex interplay of overwhelming systemic inflamma-
tion and paradoxical lack of host response, resulting in
recalcitrant vasoplegia and variably some degree of car-
diac dysfunction [4]. CS, on the other hand, results from
acutely depressed cardiac output secondary to cardiac
pump failure, with myocardial infarction as its most com-
mon cause and systemic inflammation evolving later in re-
sponse. Both types of circulatory shock are associated with
high mortality: 30% for SS [5] and 40% in CS [6]. The mo-
lecular mechanisms of SS have been widely studied with –
omic approaches in patient cohorts [7–14]. Conversely,
the molecular factors involved in CS have been poorly
studied and up to now no –omic data are available. We
performed a longitudinal study with a time course RNA
sequencing analysis in order to explore the transcriptome
in the whole blood of septic and cardiogenic shock pa-
tients during the first 7 days of ICU stay. The purpose of
this pilot analysis was to highlight the transcriptomic sig-
natures common to CS and SS, using septic patients with-
out shock as controls.
Methods
Study design and participants
This study was part of the multicenter prospective ob-
servational trial ShockOmics (ClinicalTrials.gov identi-
fier: NCT02141607, EU grant #602706). Patients were
recruited from the ICUs of the Hôpitaux Universitaires
de Genève, Université de Genève (Geneva, Switzerland),
and Hôpital Erasme, Université Libre de Bruxelles
(Brussels, Belgium). The clinical protocol was approved
by the ethical committees of the two participating insti-
tutions, and informed consent was obtained from the
patients or their representatives. In the present study, we
included consecutive adult (> 18 years old) patients
admitted to the ICU for SS or CS with a SOFA score at
admission > 6 and arterial lactate > 2 mmol/L, as previ-
ously described [15]. Moreover, patients had to have
blood samples, for the analysis of gene expression,
collected at three time points: T1, within 16 h of ICU ad-
mission; T2, 48 h after study enrollment; and T3, on day 7
from ICU admission or before discharge from the ICU. Ex-
clusion criteria were expected death within 24 h of ICU ad-
mission, transfusion of ≥ 4 units of packed red blood cells
or infusion of ≥ 1 unit of fresh frozen plasma, active
hematological malignancy, metastatic cancer, chronic im-
munosuppression, pre-existing end-stage renal disease re-
quiring renal replacement therapy, recent cardiac surgery,
Child-Pugh C cirrhosis, and terminal illness.
Septic patients without shock were included in the
study as negative controls. Admission criteria for these
patients were a proven or clinically suspected infection,
associated with at least one organ dysfunction but the
cardiovascular system, as indicated by SOFA score, and
lactate levels < 2 mmol/L. In these patients, blood sam-
ples were collected at two time points: T1, within 16 h of
ICU admission, and T2, 48 h after study enrollment.
Analysis of laboratory and clinical variables
Laboratory and clinical variables measured at the available
time points were analyzed using a linear mixed model ac-
counting for fixed effects of time, gender, age, and random
effects of patients. We identified the differences between
CS, SS, and SC with ANOVA. Demographic variables and
variables with one measurement at a single time point
were compared using the Wilcoxon rank-sum test or
Fisher exact test for categorical variables.
Blood collection and RNA extraction
Peripheral blood was collected at the time points fore-
seen by the study design in EDTA tubes with 400 μL of
2× Denaturing solution (Ambion, Austin, TX, USA) and
stored at − 20 °C. Total RNA was extracted from 800 μL
of blood with the MirVana Paris Kit and treated with
Turbo DNA-free Kit (Ambion). RNA concentration was
estimated with a Nanoquant Infinite M200 instrument
(Tecan, Austria). RNA quality was assessed on an Agi-
lent Bioanalyzer using the RNA 6000 Nano Kit (Agilent,
Santa Clara, CA, USA), and samples with RNA integrity
number > 7.5 were considered acceptable for processing.
Library preparation
We prepared sequencing libraries with the TruSeq
Stranded Total RNA with Ribo-Zero Globin Kit (Illu-
mina, San Diego, CA, USA) using 800 ng of total RNA
input. Final libraries were validated with the Agilent
DNA1000 kit and sequenced on a HiSeq2500 platform,
producing 50 × 2 base paired-end reads.
Sequencing data analysis
We aligned high-quality paired-end reads to the human
reference genome (GRCh38) using STAR (version
2.5.2b) [16], and we selected only uniquely mapping
reads. We assigned sequencing reads to genes with fea-
tureCounts (version 1.5.1) [17] using the gencode
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(version 25) primary assembly gene transfer file (GTF)
as a reference annotation file for genomic feature
boundaries.
Exploratory and differential expression analysis
DESeq2 [18] package built-in functions were used for
data preprocessing, exploratory data analysis and ana-
lysis of differential gene expression. We studied gene
expression changes over time in CS and SS patients and
SC separately with a paired analysis, comparing T1 to
T2 in SS and SC and T1 to T3 in CS and SS. Genes with
padj < 0.01—Benjamini-Hochberg multiple test correc-
tion (FDR)—were considered differentially expressed
(DEGs) and used for downstream analysis.
Gene set enrichment analysis
We first performed gene set enrichment analysis (GSEA)
[19] to identify the biological processes enriched in CS,
SS, and SC. For this purpose, the lists of genes were
ranked for log2FC (T2 vs T1 for SS and SC, and T3 vs
T1 for CS) and used as input for GSEA, together with
the gene set database c5.bp.v6.2.symbols.gmt. As the first
step, we selected significant GSEA terms (FDR < 0.1) in
at least one type of shock and filtered for the number of
DEGs ≥ 5 in CS and SS. GOs common to the two types
of shock, as well as specific of shock type (CS vs SS),
were manually selected from the dataset. Starting from
the identified GO terms, we selected a list of genes
showing significant modulation over time in CS and SS,
but not modulated in SC.
Analysis of transcriptional regulators
Gene set enrichment analysis of transcription factor tar-
gets (TFT) was performed on the lists of CS and SS
genes ranked for log2FC expression between T1 and T3.
Enriched gene sets were filtered for FDR < 0.1 and num-
ber of DEGs ≥ 10.
Results
Patients
Seventy-nine shock patients were recruited between No-
vember 2014 and March 2016 in the frame of ShockO-
mics trial. Twenty-one septic shock and 11 cardiogenic
shock patients (Additional file 1) were eligible for the
present study, after excluding 16 patients who did not
meet the inclusion criteria and 31 patients who did not
have blood samples collected at the three time points
(Additional file 2). Five septic patients, not developing
shock, were recruited as controls (SC) and followed for
two time points.
At ICU admission, there were no significant demo-
graphic differences between the CS and SS group, in-
cluding age, BMI, severity of illness (APACHEII), and
needs for norepinephrine. In both groups, about 20% of
patients died later in the period from the second to the
fourth week, after study enrollment. SOFA and lactate
levels decreased over the measured 1 week of ICU stay
in all patients. We assessed SOFA score in patients clas-
sified according to mortality (alive or dead at 28 days),
showing that a decreasing trend of SOFA can be appre-
ciated also in patients who died (Additional file 3). La-
boratory results from the blood collected at the three
time points of interest, however, revealed significant dif-
ferences between cardiogenic and septic shock patients
for C-reactive protein (CRP) level, lymphocyte count,
hematocrit, and fibrinogen (p < 0.05) (Table 1). Diastolic
blood pressure, mean arterial pressure, and temperature
were significantly different as well (Table 1). SC com-
pared to SS patients showed significant lower severity
scores (APACHE II and SOFA) at ICU admission
(Table 2) and did not develop any circulatory failure
later during the course of the ICU stay. Clinical and la-
boratory variables in SC and SS patients are available in
Additional file 7.
Sequencing experiment
Total RNA libraries were sequenced in several batches, pro-
ducing 28.61M± 6.49M, 31.32M± 7.81M, and 28.47 ±
4.37 raw read pairs on average for CS, SS, and SC groups,
respectively. Ribosomal depletion was effective for all sam-
ples; the rRNA rate on mapped data was negligible in both
groups (0.77 ± 1.25%, 0.80 ± 0.92%, and 1.38 ± 1.44% for CS,
SS, and SC, respectively). The percentages of reads mapping
to exons (85.20 ± 5.66% exonic rate) and DNase efficiency
(3.02 ± 1.96% intergenic rate) were satisfactory in all sam-
ples. We obtained on average 12.19 ± 2.82, 14.12 ± 4.20,
and 13.29 ± 1.62 million of uniquely and unambiguously
mapped fragments for the CS, SS, and SC groups,
respectively.
Gene expression analysis over time
To explore whole gene expression modifications in CS,
SS, and SC patients across the time points of the study, we
first performed a principal component analysis (PCA)
separately in each group of patients (Fig. 1a–c). PCA was
performed on the 2000 most variable genes across sam-
ples. This analysis revealed that SS patients mostly clus-
tered together according to time point on PC1, suggesting
that the largest gene expression variation in the dataset
was related to the time point (Fig. 1b). Also, in SC pa-
tients, we could appreciate a difference between the time
points (Fig. 1c). In CS, on the contrary, patients clustered
according to T3 only, but not to T1 and T2, suggesting
minor gene expression changes between these two time
points (Fig. 1a). Following this analysis, we independently
identified genes that are differentially expressed (DEGs) in
CS, SS, and SC patients over time. We found that SS pa-
tients modulated a higher number of genes compared
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Table 1 Clinical and laboratory variables with follow-up for 1 week
Clinical variable Shock T1 T2 T3 p value
Heart rate, bpm CS 87 (9) 90 (15) 92 (23) 0.69532
SS 91 (22) 81 (13) 88 (22)
Systolic blood pressure, mmHg CS 84 (11) 105 (24) 113 (34) 0.31639
SS 83 (11) 97 (16) 110 (17)
Diastolic blood pressure, mmHg CS 51 (7) 52 (9) 63 (17) 0.01147
SS 45 (4) 49 (5) 53 (12)
Mean arterial pressure, mmHg CS 61 (6) 69 (14) 79 (21) 0.04505
SS 57 (5) 64 (7) 72 (12)
Respiratory rate, rpm CS 21 (5) 26 (7) 27 (3) 0.82505
SS 25 (8) 25 (6) 27 (8)
PaO2, mmHg CS 92 (44) 79 (15) 77 (12) 0.17879
SS 85 (17) 76 (18) 70 (11)
PaCO2, mmHg CS 35.0 (13.7) 39.3 (6.5) 38.8 (5.6) 0.10633
SS 44.1 (13.0) 40.3 (8.5) 38.5 (6.9)
SvcO2% CS 64 (11) 67 (5) 86 (7) 0.49098
SS 73 (6) 69 (8) 61 (17)
FiO2 CS 0.59 (0.30) 0.35 (0.08) 0.33 (0.08) 0.87275
SS 0.52 (0.20) 0.34 (0.10) 0.33 (0.08)
PaO2/FiO2 CS 189 (109) 239 (70) 250 (73) 0.51411
SS 194 (103) 245 (89) 229 (64)
Temperature, °C CS 36.7 (1.5) 37.3 (0.8) 36.7 (1.0) 0.01178
SS 37.6 (0.9) 37.5 (0.9) 37.5 (1.3)
Urine output, mL/day CS 1492 (851) 2184 (926) 1963 (1323) 0.18808
SS 1494 (831) 2272 (1057) 2591 (1219)
Fluid balance, mL CS 1427 (1417) 197 (1104) − 17 (1267) 0.59677
SS 2591 (1958) 411 (1529) − 815 (1358)
HCO3, mmol/L CS 18.1 (3.9) 26.0 (3.9) 27.6 (3.6) 0.57272
SS 19.8 (3.9) 25.1 (4.8) 27.0 (5.0)
Norepinephrine, μg/(kg min) CS 0.23 (0.2) 0.20 (0.22) 0.16 (0.13) 0.58250
SS 0.35 (0.29) 0.23 (0.34) 0.05 (0.02)
Bilirubin, mg/dL CS 1.1 (0.6) 0.9 (0.4) 0.8 (0.6) 0.56664
SS 1.6 (1.8) 1.2 (1.4) 1.0 (1.2)
Glycemia, mg/dL CS 218.2 (73.6) 146.9 (25.1) 140.9 (54.4) 0.37518
SS 183.9 (84.8) 142.8 (37.9) 129.8 (34.3)
Prothrombin time INR CS 1.5 (0.8) 1.2 (0.5) 1.1 (0.1) 0.09433
SS 1.3 (0.3) 1.1 (0.2) 1.1 (0.2)
Fibrinogen, g/L CS 4.11 (1.46) 4.34 (2.33) 7.15 (1.68) 0.02844
SS 5.32 (2.14) 6.35 (2.13) 6.81 (1.53)
CRP value, mg/L CS 62.8 (49.3) 149.7 (74.8) 75.5 (39.2) 0.00001
SS 248.5 (140.6) 248.3 (112.5) 120.4 (71.0)
Creatinine, mg/dL CS 1.4 (0.5) 1.3 (0.6) 1.0 (0.4) 0.61095
SS 1.9 (1.4) 1.4 (1.1) 1.1 (0.7)
Lactate levels, mmol/L CS 4.9 (3.6) 1.2 (0.4) 1.2 (0.5) 0.84012
SS 4.3 (2.4) 1.7 (0.8) 1.2 (0.5)
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to CS patients both in the comparison T2 vs T1
(CS = 12, SS = 3474) and T3 vs T1 (CS = 1073, SS =
6173). In the SC group, we detected 130 DEGs in the
comparison T2 vs T1.
Gene set enrichment analysis
Based on the exploratory analysis, we analyzed with
GSEA the genes identified in each group, with the
aim to pinpoint overrepresented classes of genes and
Gene Ontology (GO) terms that describe the under-
lying biological processes. We used as input for GSEA
the genes of the comparison between T1 and T2, sep-
arately in SS and SC. In CS, we analyzed the com-
parison T1 vs T3, because this is the time frame in
which relevant gene expression differences were
observed. We first selected GO terms significantly
enriched in at least 1 type of shock, and we found a
total of 315 downregulated and 78 upregulated bio-
logical processes (Additional file 4). GO terms of the
inflammatory response and pattern recognition recep-
tors (PRR) were downregulated over time, whereas
GO terms related to DNA replication were
upregulated in both CS and SS. We selected a list of
inflammatory, PRR, and DNA replication genes show-
ing significant modulation over time in CS and SS
but not modulated in SC (Fig. 2, Table 3). In detail,
we observed a negative expression trend for alarmins
(S100A8, S100A9, S100A12), components of the
inflammasome (NAIP, NLRC4), genes related to inter-
leukin receptors (IL10RB, IL17RA, IL4R), transcription
Table 1 Clinical and laboratory variables with follow-up for 1 week (Continued)
Clinical variable Shock T1 T2 T3 p value
SOFA CS 11.0 (2.5) 7.5 (2.8) 5.2 (3.0) 0.36026
SS 12.1 (2.0) 8.8 (3.0) 5.5 (3.3)
Glasgow Coma Scale CS 6 (4) 10 (3) 13 (3) 0.36746
SS 5 (4) 9 (3) 11 (3)
Platelets, 103/mm3 CS 260 (85) 208 (80) 295 (138) 0.16299
SS 205 (103) 176 (84) 235 (107)
Hematocrit % CS 39.2 (4.0) 34.9 (4.9) 35.2 (4.4) 0.00360
SS 34.6 (5.0) 30.2 (5.2) 31.4 (4.4)
Leukocytes total, 103/mm3 CS 15.92 (5.36) 12.09 (4.20) 10.83 (2.93) 0.90718
SS 16.19 (13.94) 14.55 (7.67) 13.66 (5.36)
White blood cells, 109/L CS 15.29 (6.00) 12.2 (4.61) 11.29 (2.95) 0.98992
SS 15.96 (14.22) 14.49 (7.95) 13.98 (5.59)
Lymphocytes, 109/L CS 1.41 (0.70) 1.37 (0.65) 1.54 (0.67) 0.00007
SS 0.70 (0.60) 0.80 (0.54) 0.90 (0.47)
Neutrophils, 109/L CS 10.75 (6.27) 10.50 (5.95) 7.60 (1.38) 0.10346
SS 14.49 (7.22) 11.32 (2.25) 12.14 (2.75)
Clinical and laboratory characteristics of the patients divided by cardiogenic shock (CS) and septic shock (SS). Data are presented as mean (SD). p values were
calculated with ANOVA and describe the significance of the difference between the variables in cardiogenic shock and septic shock over the three time points
Table 2 Clinical variables
Clinical variable CS (n = 11) SS (n = 21) SC (n = 5) p value SS vs CS p value SS vs SC
Age, years 68.7 (13.0) 67.5 (19.2) 72.4 (15.8) 0.937 0.696
Body mass index, kg/m2 27.8 (6.9) 27.2 (5.5) 22.1 (6.9) 0.721 0.111
Sex, males 10 (90.9%) 14 (66.6%) 3 (60.0%) 0.210 1.000
Length of stay in ICU, days 7.6 (3.3) 9.2 (6.0) 6.0 (6.7) 0.920 0.046
Length of stay in hospital, days 24.2 (18.3) 28.0 (19.5) 28.0 (26.1) 0.676 0.696
APACHE II (T1) 22.73 (7.34) 24.57 (7.51) 14.6 (3.0) 0.450 0.012
SOFA (T1) 11.0 (2.5) 12.1 (2.0) 6.2 (2.2) 0.360 0.001
Mortality (28 days) 2 (18.2%) 5 (23.8%) 0 (0%) 1.000 0.545
Clinical characteristics of the patients divided by cardiogenic shock (CS), septic shock (SS), and septic controls (SC). Data are presented as mean (SD) or frequency
(%). p values were calculated with Wilcoxon rank-sum test or alternatively with Fisher exact test for categorical variables
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factors (CEBPB, PPARG, RBPJ, BCL6), Toll-like recep-
tors (TLR1, TLR4, TLR8), and C-type lectin receptors
(CLEC5A, CLEC6A). A positive expression trend was
observed for genes essential for DNA replication
(MCM2, MCM3, MCM5, MCM7). We also estimated
the gene expression modifications in SS and CS com-
paring T1 to T3. In SS patients only, we found in-
creasing expression of genes involved in defense
response to bacteria and lymphocyte-mediated im-
munity, as well as decreasing expression of genes in-
volved in platelet function and carbohydrate catabolic
processes (Additional file 5, Additional file 8). Im-
munoglobulin genes encoding the heavy constant
chains (IGHA1, IGHA2, IGHG1, IGHG2, IGHG3,
IGHG4, IGHGP, IGHM) and the variable heavy and
light chains (IGHV, IGKV, IGLV gene classes) were
upregulated over 1 week of observation in both types
of shock (Table 4).
Analysis of transcription factor target genes
We searched for overrepresented transcription factor tar-
gets in the lists of genes ranked according to log2FC in the
CS and SS groups separately. GSEA results are as shown
in Additional file 6. Then, we focused on the common
enriched transcription factors: we observed that genes
with a negative expression trend were enriched in target
sequences of CCAAT-enhancer-binding protein beta
(CEBPB), whereas positively regulated genes were
enriched in target sequences of the members of the E2F
family of transcription factors (Table 5, Fig. 3).
Discussion
This study describes the transcriptome profile of circu-
lating cells in CS and SS patients over the first week
after ICU admission, using septic patients without shock
as controls. The study design is based on three time
points (T1, T2, T3) over 1 week of observation in shock
patients and two time points (T1, T2) in septic controls.
To our knowledge, an analysis with this time frame from
shock onset is new in the field of SS research, and this is
the first transcriptomic study in CS.
At study enrollment, illness severity, evaluated as
SOFA score and lactate level, was comparable between
CS and SS patients and decreased during 1 week of ICU
stay. The dosage of norepinephrine needed to maintain
blood pressure was also similar between the two groups,
demonstrating a comparable degree of vasoplegia. How-
ever, significant differences were found in the levels of
C-reactive protein and lymphocyte count that could be
explained by the pathophysiology of the two types of
shock.
Within-group transcriptomic analysis over time showed
differences in the number of genes modulated in SS and
CS during the period of observation, with a larger number
Fig. 1 PCA plot of CS and SS patients. PCA plot of CS patients at three
time points (a). PCA plot of SS patients at three time points (b). PCA
plot of SC patients at T1 and T2 (c). PCs were adjusted in order to
remove the patient effect
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of differentially expressed genes identified in SS compared
to CS. The timing of gene expression modulation was dif-
ferent as well, compared to the time of shock diagnosis
(T1). SS patients showed significant modifications both in
the early phase that corresponds to T2 and after 7 days of
ICU stay (T3), whereas in CS patient, relevant and signifi-
cant transcriptomic changes occurred only at T3. Differ-
ential expression in these time frames identified genes and
pathways common to both CS and SS groups, but not
found in SC. Among the genes identified in both shock
groups, GSEA highlighted a negative expression trend for
genes involved in inflammatory processes including alar-
mins, inflammasome, and interleukin receptors, implying
that the acute phase of shock in these patients was charac-
terized by an inflammatory peak that decreased after
supportive treatment. From our results, it appears that at
the transcriptional level inflammatory processes are more
rapidly downregulated in SS (Fig. 2) and more slowly in
CS patients. A different timing of the inflammatory pro-
cesses in CS and SS was also suggested by the trend of
CRP serum levels in the three time points (Fig. 4). A simi-
lar time course of the expression of C-reactive protein has
been previously described by Parenica et al. [20].
In both CS and SS patients, SOFA scores showed a
decreasing trend in time, suggesting a link between acute
inflammation and organ dysfunction as it has been pre-
viously found in acute illness [21]. Pattern recognition
receptors (PRRs), including Toll-like receptors (TLRs)
and C-type lectin receptors, were downregulated after
1 week in both shock types. PRRs are essential for the
Fig. 2 Inflammatory pathway, pattern recognition receptors, and DNA replication. Expression trends of significantly modulated genes in CS and
SS, but not in SC patients. Data are normalized on T1; log2FoldChanges are plotted
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Table 3 Gene expression changes in inflammatory pathway, pattern recognition receptors, and DNA replication
Gene name Category Molecular function CS_log2FC_T1T3 SS_log2FC_T1T2
BCL6 Inflammation Transcription factor − 0.68 − 0.58
CCR1 Inflammation Chemokine receptor − 0.67 − 0.61
CD55 Inflammation Regulation of complement cascade − 0.77 − 1.00
CEBPB Inflammation Transcription factor − 0.63 − 0.79
CYP19A1 Inflammation Aromatase—estrogen synthesis − 1.28 − 1.23
EDNRB Inflammation Endothelin receptor − 0.79 − 0.90
FCER1G Inflammation Antibody receptor − 0.55 − 0.80
FLOT1 Inflammation Vesicle trafficking and cell morphology − 0.60 − 0.77
IL10RB Inflammation Interleukin receptor − 0.48 − 0.50
IL17RA Inflammation Interleukin receptor − 0.47 − 0.35
IL4R Inflammation Interleukin receptor − 0.58 − 0.82
MAPK14 Inflammation MAPK p38 − 0.58 − 0.75
NAIP Inflammation Inflammosome − 0.63 − 0.80
NLRC4 Inflammation Inflammosome − 0.63 − 0.73
PPARG Inflammation Transcription factor − 1.07 − 0.78
PTPN22 Inflammation Tyrosine phosphatase − 0.43 − 0.65
RBPJ Inflammation Transcription factor − 0.61 − 0.34
REL Inflammation NF-KB subunit − 0.36 − 0.29
S100A12 Inflammation Alarmin − 0.71 − 1.17
S100A8 Inflammation Alarmin − 0.60 − 0.78
S100A9 Inflammation Alarmin − 0.53 − 0.54
SBNO2 Inflammation Transcriptional regulation of NF-kappaB − 0.56 − 0.38
STAT3 Inflammation Transcription factor − 0.42 − 0.43
UBC Inflammation Polyubiquitin precursor − 0.38 − 0.26
VAMP3 Inflammation Vesicular transport − 0.35 − 0.46
VNN1 Inflammation Leucocyte adhesion and migration − 0.67 − 0.97
CLEC5A Pattern recognition receptor C-type lectin receptor − 0.63 − 1.42
CLEC6A Pattern recognition receptor C-type lectin receptor − 0.75 − 1.07
IRAK3 Pattern recognition receptor PRR downstream signaling − 0.78 − 0.51
TLR1 Pattern recognition receptor Toll-like receptor − 0.58 − 0.39
TLR4 Pattern recognition receptor Toll-like receptor − 0.74 − 0.53
TLR8 Pattern recognition receptor Toll-like receptor − 0.66 − 0.44
DNAJA3 DNA replication Interactor of DNA polymerase 0.41 0.34
FEN1 DNA replication DNA replication and repair 0.83 0.59
GINS2 DNA replication DNA replication initiation 1.18 0.79
HIST1H4I DNA replication Replication-dependent histone 0.53 0.57
MCM2 DNA replication MCM complex 0.88 0.76
MCM3 DNA replication MCM complex 0.54 0.60
MCM5 DNA replication MCM complex 0.36 0.36
MCM7 DNA replication MCM complex 0.48 0.55
RRM1 DNA replication Biosynthesis of deoxyribonucleotides 0.43 0.36
RUVBL1 DNA replication DNA helicase 0.51 0.37
Genes with significant modulation over time in both CS and SS, but not in SC. Description of functions and log2FoldChange expression are shown
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Table 4 Gene expression changes of immunoglobulins
Gene ID Gene name Chain Region Antibody class CS_log2FC_T1T3 SS_log2FC_T1T3
ENSG00000211895 IGHA1 Heavy Constant IgA 1.25 1.48
ENSG00000211890 IGHA2 Heavy Constant IgA 1.27 1.52
ENSG00000211896 IGHG1 Heavy Constant IgG 1.05 1.15
ENSG00000211893 IGHG2 Heavy Constant IgG 1.28 2.15
ENSG00000211897 IGHG3 Heavy Constant IgG 1.14 1.28
ENSG00000211892 IGHG4 Heavy Constant IgG 0.95 1.52
ENSG00000253755 IGHGP Heavy Constant IgG 0.99 1.30
ENSG00000211899 IGHM Heavy Constant IgM 0.98 0.84
ENSG00000211934 IGHV1-2 Heavy Variable – 0.92 1.25
ENSG00000211935 IGHV1-3 Heavy Variable – 0.91 1.13
ENSG00000211962 IGHV1-46 Heavy Variable – 0.72 1.17
ENSG00000211942 IGHV3-13 Heavy Variable – 0.89 1.36
ENSG00000211943 IGHV3-15 Heavy Variable – 1.37 1.62
ENSG00000211947 IGHV3-21 Heavy Variable – 1.11 1.25
ENSG00000211949 IGHV3-23 Heavy Variable – 1.35 1.30
ENSG00000270550 IGHV3-30 Heavy Variable – 1.10 1.17
ENSG00000211964 IGHV3-48 Heavy Variable – 1.09 1.15
ENSG00000211965 IGHV3-49 Heavy Variable – 0.87 1.22
ENSG00000282639 IGHV3-64D Heavy Variable – 1.11 1.31
ENSG00000211938 IGHV3-7 Heavy Variable – 1.43 1.65
ENSG00000225698 IGHV3-72 Heavy Variable – 1.73 1.46
ENSG00000211976 IGHV3-73 Heavy Variable – 1.11 1.73
ENSG00000224650 IGHV3-74 Heavy Variable – 1.24 1.56
ENSG00000211959 IGHV4-39 Heavy Variable – 0.87 1.08
ENSG00000276775 IGHV4-4 Heavy Variable – 0.93 1.26
ENSG00000224373 IGHV4-59 Heavy Variable – 1.11 1.05
ENSG00000211966 IGHV5-51 Heavy Variable – 0.85 1.00
ENSG00000211933 IGHV6-1 Heavy Variable – 1.25 1.16
ENSG00000211592 IGKC Light Constant – 1.30 1.48
ENSG00000211597 IGKJ1 Light Joining – 0.89 1.21
ENSG00000211594 IGKJ4 Light Joining – 0.89 1.19
ENSG00000243290 IGKV1-12 Light Variable – 1.28 0.94
ENSG00000240864 IGKV1-16 Light Variable – 1.11 1.01
ENSG00000240382 IGKV1-17 Light Variable – 1.26 1.43
ENSG00000244575 IGKV1-27 Light Variable – 1.21 1.05
ENSG00000243466 IGKV1-5 Light Variable – 1.10 1.39
ENSG00000239855 IGKV1-6 Light Variable – 1.07 1.65
ENSG00000241755 IGKV1-9 Light Variable – 1.08 1.17
ENSG00000241294 IGKV2-24 Light Variable – 1.13 1.71
ENSG00000243238 IGKV2-30 Light Variable – 1.24 1.50
ENSG00000243264 IGKV2D-29 Light Variable – 1.10 1.32
ENSG00000241351 IGKV3-11 Light Variable – 1.43 1.14
ENSG00000244437 IGKV3-15 Light Variable – 1.08 1.23
ENSG00000239951 IGKV3-20 Light Variable – 1.20 1.46
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early detection of pathogens and the initiation of an
adequate innate immune response [22, 23], and they play
a well-known role in the development and pathogenesis
of sepsis [24]. PRRs can also be activated by damage-
associated molecular patterns (DAMPs) [25–27], which
act as triggers of inflammation, cell injury, vascular
leakage, and multiple organ dysfunction in acute illness
[24, 28, 29]. This may be a possible explanation for the
inflammatory modulation observed in CS patients, as the
involvement of pattern recognition receptor signaling
and inflammatory mediators has been documented in
the pathogenesis of heart failure [30–32] and lung injury
[33]. Transcription factors with inflammation-related
associations also displayed a decreasing expression trend,
including peroxisome proliferator-activated receptor gamma
(PPARG), a regulator of inflammation and the lipid pathway,
and CCAAT-enhancer-binding protein beta (CEBPB), which
is necessary for normal macrophage inflammatory
response [34]. Decreases in these inflammation-related
transcription factors correlated significantly with the
decreased expression of a set of genes related to inflam-
mation and immunity.
During the critical illness period from T1 to T3, we
observed a positive expression trend of DNA replication
Table 4 Gene expression changes of immunoglobulins (Continued)
Gene ID Gene name Chain Region Antibody class CS_log2FC_T1T3 SS_log2FC_T1T3
ENSG00000211625 IGKV3D-20 Light Variable – 1.02 1.31
ENSG00000211598 IGKV4-1 Light Variable – 1.27 1.72
ENSG00000211677 IGLC2 Light Constant – 1.26 1.52
ENSG00000211679 IGLC3 Light Constant – 1.32 1.45
ENSG00000211642 IGLV10-54 Light Variable – 1.09 1.17
ENSG00000211653 IGLV1-40 Light Variable – 1.05 1.21
ENSG00000211651 IGLV1-44 Light Variable – 0.97 1.32
ENSG00000211648 IGLV1-47 Light Variable – 1.03 1.63
ENSG00000211644 IGLV1-51 Light Variable – 1.16 1.24
ENSG00000211668 IGLV2-11 Light Variable – 1.08 1.57
ENSG00000211666 IGLV2-14 Light Variable – 1.21 1.62
ENSG00000211660 IGLV2-23 Light Variable – 1.21 1.70
ENSG00000278196 IGLV2-8 Light Variable – 1.44 1.57
ENSG00000211673 IGLV3-1 Light Variable – 0.79 1.15
ENSG00000211663 IGLV3-19 Light Variable – 0.82 1.21
ENSG00000211662 IGLV3-21 Light Variable – 0.89 1.08
ENSG00000211637 IGLV4-69 Light Variable – 0.94 1.19
ENSG00000211650 IGLV5-45 Light Variable – 0.83 0.96
ENSG00000211640 IGLV6-57 Light Variable – 1.08 1.33
ENSG00000211652 IGLV7-43 Light Variable – 1.13 1.65
ENSG00000211649 IGLV7-46 Light Variable – 1.06 1.76
ENSG00000211638 IGLV8-61 Light Variable – 1.13 1.62
Genes with significantly different expression in both CS and SS over 1 week. Description of functions and log2FoldChange expression are shown
Table 5 GSEA of transcription factor targets (TFT)
Gene set (TFT) CS_NES SS_NES CS_FDR.q.val SS_FDR.q.val DEGs_CS DEGs_SS Trend
CEBPB_02 − 1.80 − 1.87 0.08739 0.02342 23 56 Negative
E2F_Q3_01 1.99 1.64 0.00111 0.02955 20 54 Positive
E2F_Q4_01 1.89 1.87 0.00144 0.01000 20 57 Positive
E2F_Q6 1.95 1.55 0.00117 0.06391 18 58 Positive
E2F_Q6_01 1.93 1.65 0.00128 0.03002 20 54 Positive
E2F1_Q4_01 1.92 1.63 0.00123 0.03049 20 52 Positive
For each gene set of TFT is reported: normalized enriched score, false discovery rate, the number of target genes differentially expressed in CS and SS, and the
gene expression trend
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genes (Fig. 2) in both SS and CS groups, suggesting that
during shock, at least, a subset of circulating cells under-
goes a process of self-renewal. In this time frame, we
also observed the upregulation of immunoglobulins, im-
plying an activation of the adaptive immune system that
is co-existent with innate immune system downregula-
tion. Consistent with our observations, low serum levels
of circulating immunoglobulins have been described at
septic shock onset [35–37], and Venet et al. observed
their increase to reference levels after 5–7 days [38].
Interestingly, the increasing trend of immunoglobulin
gene transcription in SS was also observed in CS pa-
tients, suggesting that Igs may also have a role in the ab-
sence of infection. This is in agreement with the findings
of Andaluz-Ojeda et al. who investigated the role of Ig
in non-septic critically ill patients [39]. The role of Igs in
the absence of infection may be related both to the de-
tection of DAMPs [40] and to the immunomodulatory
activity of the adaptive immune response [41]. The ana-
lysis of transcription factor targets in the CS and SS
groups revealed a significant enrichment of genes regu-
lated by the E2F transcription factor family, which are
involved in the control of cell cycle progression and cell
proliferation [42, 43].
In this study, we could also focus on genes that modify
their expression uniquely in SS. In these patients, as
expected, specific transcriptomic modifications were ob-
served in genes involved in the response to infection,
lymphocyte-mediated immunity, carbohydrate metabol-
ism, and platelet function. These processes are impli-
cated in the pathophysiology of sepsis and have already
been described in previous works [44–46]. In CS
patients, our study was unable to detect any specifically
modulated pathway in the blood cells; transcriptional
modifications observed in this group were associated
with biological functions common to SS.
The present work has two limitations. The first is the
small sample size, which could hamper the detection of
small, but still relevant gene expression changes. More-
over, studies of large cohorts [47] and the poor success
of the past clinical trials [48] showed that sepsis is a
heterogeneous condition, with high between-patient vari-
ability, and looking at a small cohort of patients make dif-
ficult the identification of different phenotype subgroups.
The same concept is extendible to cardiogenic shock
patients, as they also could show phenotypes or different
heart failure and circulatory shock mechanisms [32]. To
partially overcome between-patient variability, we used a
Fig. 3 Gene expression trends of enriched transcription factor targets in CS and SS. CEBPB and E2F target genes are shown. Data are normalized
on T1; log2FoldChanges are plotted
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paired analysis to assess the gene expression changes,
which takes advantage of the within-patient correlation
between the time points, strengthens the analysis, and im-
proves the statistical power.
A second limitation is that, since we used a study
design based on three time points, we have excluded
the most severe patients who died before the second
or third time point. Thus, the results of our study de-
scribe only patients surviving at least 1 week, whereas
patients who died early could have different expres-
sion signals. The exclusion of the most severe pa-
tients can also explain why mortality in our shock
patients was low in comparison with broader modern
clinical trials or large surveys. In addition, in our car-
diogenic shock patients, the amount of CS not related
to an acute coronary syndrome was 7/11 (Add-
itional file 1), a condition that is associated with a
mortality rate < 25% as reported by Harjola et al. [49].
In short, our study pinpoints a common modulation
in SS and CS patients of genes of inflammation,
PRRs, DNA replication, and immunoglobulins, irre-
spective of the etiology. These pathways have been
previously investigated in SS, and their perturbation
can be interpreted as the response of the immune
system to a widespread infection. Their modulation in
CS patients suggests that their role may be
independent of infection and sepsis and should rather
be seen in the context of dysfunctions associated with
circulatory shock. The overlap in molecular patterns
observed in this study suggests shared mechanistic
pathways between CS and SS. This could help to
identify common targets for more personalized ther-
apies that can be used in different critical illness con-
ditions [50], as previously demonstrated and is
ongoing in cancer research [51].
Conclusions
Our preliminary results support a central role for acute in-
flammatory processes in the pathophysiology of shock,
with the hypothesis that pattern recognition receptors,
alarmins, and immunoglobulins may serve as mediators.
This study has the limit of a small sample size. However, it
encourages new –omics studies in larger cohorts of circu-
latory shock patients to investigate the relationships of
PRRs, inflammation, and immunoglobulins with outcomes.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13054-019-2670-8.
Additional file 1: Table S1. Description of CS, SS and SC patients
included in the study. For each patient is reported the type of shock,
Fig. 4 Boxplots of C-reactive protein serum measurements. C-reactive protein measurements (mg/L) in cardiogenic and septic shock patients
measured at three time points. The lower and upper hinges correspond to the 25th and 75th percentiles, respectively
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gender and age, mortality at 28 days. The cause for CS is specified for CS
patients, whereas for SS and SC patients the source of infection is
indicated.
Additional file 2: Figure S1. Flow Chart of the process of patient
recruitment. Description of the process of selection of the patients
included in the study.
Additional file 3: Figure S2. SOFA score trends in CS and SS patients
according to mortality. Boxplots of SOFA scores evaluated at three
timepoints in CS and SS patients according to the mortality at 28 days.
Additional file 4. Results of GSEA of Gene Ontologies in CS and SS.
Upregulated (Excel Sheet “GSEA_UP”) and downregulated (Excel Sheet
“GSEA_DOWN”) gene sets resulting from the GSEA analysis in CS, SS and
SC. For each significantly enriched GO is reported the number of DEGs,
the Normalized Enriched Score (NES), the False Discovery Rate (FDR.q.val).
Additional file 5: Figure S3. Gene expression trends of biological
processes enriched only in SS patients. Gene expression trends of
biological processes related to defense response to bacterium,
lymphocyte mediate immunity, platelet activation and degranulation,
carbohydrate catabolic process. Data are normalized on T1,
log2FoldChanges are plotted.
Additional file 6. Results of the GSEA of Transcription Factor Targets
(TFT). Results table of the GSEA analysis of genes ranked for log2FC over
one week in CS and SS. For each gene set of TFT is reported: number of
DEGs and number of genes in the gene set (SIZE), Normalized Enriched
Score, False Discovery Rate and type of shock.
Additional file 7. Clinical variables of SS and SC patients. Clinical
characteristics of the patients divided by Septic Shock and Septic
Controls. Data are presented as mean (SD). P-values were calculated with
ANOVA and describe the significance of the difference between the
variables in Septic Shock and Septic Controls over 2 timepoints.
Additional file 8. Gene expression trends of biological processes
enriched only in SS patients. Extensive information of genes shown in
Figure S3 is reported in this table. Data are normalized on T1,
log2FoldChanges are shown.
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